Arbutus Biopharma Corp Stock Issued During Period, Value, Acquisitions
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Arbutus Biopharma Corp stock issued during period, value, acquisitions for the quarter ending 2015-12-31 was $0.00.
- Arbutus Biopharma Corp stock issued during period, value, acquisitions for the quarter ending 2015-09-30 was $0.00.
- Arbutus Biopharma Corp stock issued during period, value, acquisitions for the quarter ending 2015-06-30 was $1.13M.
- Arbutus Biopharma Corp stock issued during period, value, acquisitions for the quarter ending 2015-03-31 was $380.81M.
- Arbutus Biopharma Corp stock issued during period, value, acquisitions for fiscal 2015 was $381.94M.
| Period end | Stock Issued During Period, Value, Acquisitions 3 month | Stock Issued During Period, Value, Acquisitions 12 month |
|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $381.94M 10-K · filed 2018-03-16 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | |
| 2015-06-30 | $1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | |
| 2015-03-31 | $380.81M 10-Q · filed 2015-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |